ITi Health

Based in Charlottesville, Virginia, iTi Health, Inc. operates within the biotechnology sector, focusing on the development of novel diagnostics and therapies for several challenging cancers, including pancreatic, ovarian, esophageal, and head and neck cancers. Founded in November 2010, the company's core mission is to create personalized therapies for diseases with significant unmet medical needs.

The company's strategy is centered around two main product lines: plectin-targeted imaging and plectin-targeted therapeutics. iTi Health holds exclusive, global rights to the targeting agent compositions and the use of plectin for both diagnostic and therapeutic applications in human diseases. This positions the company to develop proprietary technology that can identify a protein biomarker in the early stages of pancreatic cancer. The business model appears to be rooted in the research and development of these biotechnologies, with the eventual goal of commercializing these products, likely through partnerships, licensing, or direct sales to healthcare providers and pharmaceutical companies.

The leadership team includes Kim Kelly, who serves as the CEO and CSO. Dr. Kelly is also an Assistant Professor of Biomedical Engineering at the University of Virginia, bringing a strong academic and research-oriented background to the company's operations. Colin Rolph is also listed as part of the team. The company is structured as a C-corp and, as of earlier records, its products are in the development stage.

Keywords: biotechnology, oncology, cancer diagnostics, cancer therapy, plectin-targeted imaging, plectin-targeted therapeutics, personalized medicine, pancreatic cancer, ovarian cancer, esophageal cancer, head and neck cancer, protein biomarker, medical research, life sciences, Charlottesville startups, Kim Kelly, Colin Rolph